[1] E. Simpson, T. Bieber and L. Eckert, “Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b on clinical trial of dupilumab in adults,” Am Acad Dermatol, vol. 74, no. 3, pp. 491-498, 2016; [2] D. Leung, R. Nicklas and J. Li, “Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters,” Ann Allergy Asthma Immunol, vol. 93, no. 3 (Suppl. 2), pp. S1-S21, 2004; [3] T.E. Shaw, G.P. Currie, C.W. Koudelka, E.L. Simpson, “Eczema prevalence in the United States: data from the 2003 National Survey of Children’s Health”, J Invest Dermatol, vol. 131, no. 1, pp. 67-73, 2011; [4] H. Williams, C. Robertson, A. Stewart, et al. “Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood”, J Allergy Clin Immunol, vol. 103, no 1, pp. 125-138, 1999; [5] N. Ballardini, I. Kull, C. Soderhall, G. Lilja, M. Wickman, C.F. Wahlgren, “Eczema severity in preadolescent children and its relation to sex, filaggrin mutations, asthma, rhinitis, aggravating factors and topical treatment: a report from the BAMSE birth cohort”, Br J Dermatol, vol. 168, no. 3, pp. 588-594, 2013; [6] S.J. Brown, C.L. Relton, H. Liao, et al., “Filaggrin null mutations and childhood atopic eczema: a population-based case-control study”. J Allergy Clin Immunol, vol. 121, no. 4, pp. 940-946, 2008; [7] S. Dhami, A. Sheikh, “Estimating the prevalence of aero-allergy and/or food allergy in infants, children and young people with moderate-to-severe atopic eczema/dermatitis in primary care: multi-centre, cross- sectional study”, J R Soc Med, vol. 108, no. 6, pp. 229-236, 2015; [8] A. Lebon, J.A. Labout, H.A. Verbrugh, et al., “Role of Staphylococcus aureus nasal colonization in atopic dermatitis in infants: the Generation R Study”. Arch Pediatr Adolesc Med., vol. 163, no. 8, pp. 745-749, 2009; [9] A.B. Olesen, K. Bang, S. Juul, K. Thestrup-Pedersen, “Stable incidence of atopic dermatitis among children in Denmark during the 1990s”, Acta Derm Venereol, vol 85, no. 3, pp. 244-247, 2005; [10] H. Saeki, H. Iizuka, Y. Mori, et al. “Prevalence of atopic dermatitis in Japanese elementary schoolchildren”, Br J Dermatol, vol. 152, no. 1., pp. 110-114, 2005; [11] J.I. Silverberg, E.L. Simpson, “Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization”, Pediatr Allergy Immunol, vol. 24, no. 5, pp.476-486, 2013; [12] World Allergy Organization, “White book on allergy: update 2013,” 2013. [Online]. Available: http://www.worldallergy.org/UserFiles/file/WhiteBook2-2013-v8.pdf. [Accessed 24 July 2017]; [13] S. Barbarot, S. Auziere, A. Gadkari, G. Girolomoni, L. Puig, E. L. Simpson, D. J. Margolis, M. de Bruin-Weller, L. Eckert, “Epidemiology of atopic dermatitis in adults: results from an international survey”, Allergy, vol. 73, no.6, pp. 1284-1293, 2018; [14] Guo, Y., et al., “Prevalence of Atopic Dermatitis in Chinese Children aged 1-7?ys”. Scientific reports, vol. 6: pp. 29751, 2016; [15] T. Bieber, “Personalized management of atopic dermatitis: beyond emollients and topical steroids”. In: T. B, F. N, eds. “Personalized treatment options in dermatology”, Springer-Verlag, pp. 61-76, 2015; [16] T. Bieber, “Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine,” Allergy, vol. 67, no. 12, pp. 1475-1482, 2012; [17] D. Garmhausen, T. Hagemann and T. Bieber, “Characterization of different courses of atopic dermatitis in adolescent and adult patients,” Allergy, vol. 68, no. 4, pp. 498-506, 2013; [18] L. Eichenfield, W. Tom and S. Chamlin, “Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis,” J Am Acad Dermatol, vol. 70, no. 2, pp. 338-351, 2014; [19] T. Bieber, “Atopic dermatitis, Mechanisms of Disease,” N Engl J Med, vol. 358, no. 14, pp. 1483-1494, 2008; [20] E. Guttman-Yassky, K. Nograles and J. Krueger, “Contrasting pathogenesis of atopic dermatitis and psoriasis--part I: clinical and pathologic concepts,” J Allergy Clin Immunol, vol. 127, no. 5, pp. 1110-1118, 2011; [21] A. Blauvelt, M. de Bruin-Weller and M. Gooderham M (2017). Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet, 389(10086), pp. 2287-2303; [22] K. Eyerich, S. Eyerich and T. Biedermann, “The Multi-Modal Immune Pathogenesis of Atopic Eczema,” Trends Immunol, vol. 36, no. 12, pp. 788-801, 2015; [23] C. Correale, C. Walker and L. Murphy, “Atopic dermatitis: a review of diagnosis and treatment,” Am Fam Physician, vol. 60, no. 4, pp. 1191-1198, 1999; [24] J. Ring, A. Alomar and T. Bieber, “Guidelines for treatment of atopic eczema (atopic dermatitis) Part I,” J Eur Acad Dermatol Venereol, vol. 26, no. 8, pp. 1045-1060, 2012; [25] E. Simpson, “Comorbidity in Atopic Dermatitis,” Curr Dermatol Rep, vol. 1, no. 1, pp. 29-38, 2012; [26] E. Simpson, E. Guttman-Yassky, D. J Margolis et al (2016). Chronicity, Comorbidity and Life Course Impairment in Atopic Dermatitis: Insights from a Cross-Sectional Study in US Adults. Poster P0301 presented at 25th EADV; (September 28–October 2, 2016, Vienna, Austria); [27] T. Zuberbier, S. Orlow and A. Paller, “Patient perspectives on the management of atopic dermatitis,” J Allergy Clin Immunol, vol. 118, no. 1, pp. 226-232, 2006; [28] A. Torrelo, J. Ortiz and A. Alomar, “Atopic dermatitis: impact on quality of life and patients’ attitudes toward its management,” Eur J Dermatol, vol. 22, no. 4, pp. 97-105, 2012; [29] J. Schmitt, F. Csotonyi, A. Bauer and M. Meurer, “Determinants of treatment goals and satisfaction of patients with atopic eczema,” J Dtsch Dermatol Ges, vol. 6, no. 6, pp. 458-465, 2008; [30] W. Wei, A. Gadkari and R. Klumph, “Burden of disease among employees with atopic dermatitis: comorbidities, healthcare resource utilization/costs, and absenteeism (abstract LO2),” J Manag Care Spec Pharm, vol. 21, no. 10-a, pp. S64-S65, 2015; [31] E. Holm, S. Esmann and G. Jemec, “The handicap caused by atopic dermatitis – sick leave and job avoidance,” J Eur Acad Dermatol Venereol, vol. 20, no. 3, p. 255–259, 2006; [32] E.E. Brenninkmeijer, C.M. Legierse, J.H. Sillevis Smitt, B.F. Last, M.A. Grootenhuis, J.D. Bos, “The course of life of patients with childhood atopic dermatitis,” Pediatr Dermatol, vol. 26, no. 1, p.14-22, 2009; [33] M. Boguniewicz, et al., “A multiple-domain framework of clinical, economic, and patient- reported outcomes for evaluating benefits of interverntion in atopic dermatitis,” J Drugs Dermatol, vol. 6, no. 4, p.416-423, 2007; [34] D. Fivenson, R. Arnold and D. Kaniecki, “The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization,” J Manag Care Pharm, vol. 8, no. 5, pp. 333-342, 2002; [35] S. M. Shrestha, L. Wang and J. Chao, “Burden of atopic dermatitis: comorbidities, healthcare resource utilization, and costs in US commercial and Medicare adult populations (abstract L02),” J Manag Care Spec Pharm, vol. 22, no. 10-a, p. S71, 2016; [36] S. Shrestha, R. Miao and L. Wang, “Burden of atopic dermatitis among adults in a State Medicaid Program (Medi-Cal) (abstract O059),” Ann Allergy Asthma Immunol, vol. 117, p. S19, 2016; [37] R. Law and P. Kwa, Atopic Dermatitis. Pharmacotherapy: A Pathophysiologic Approach, 9th ed., McGraw-Hill Education, 2014; [38] C. Akdis, M. Akdis and T. Bieber, “Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report,” J Allergy Clin Immunol, vol. 118, no. 1, pp. 152-169, 2006; [39] R. Sidbury, D. Davis and D. Cohen, “Guidelines of care for the management of atopic dermatitis. Part 3: Management and treatment with phototherapy and systemic agents,” J Am Acad Dermatol, vol. 71, no. 2, pp. 327-349, 2014; [40] T. Bieber and B. Straeter, “Off-label prescriptions for atopic dermatitis in Europe,” Allergy, vol. 70, no. 1, pp. 6-11, 2015; [41] H. Saeki, T. Nakahara and A. Tanaka, “Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016,” J Dermatol, vol. 43, no. 10, pp. 1117-1145, 2016; [42] S. Meggitt, J. Gray and N. Reynolds, “Azathioprine dosed by thiopurine methyltransferase activity for moderate to severe atopic eczema: a double-blind, randomised controlled trial,” Lancet, vol. 367, no. 9513, pp. 839-846, 2006; [43] D. Ashcroft, P. Dimmock and R. Garside, “Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta- analysis of randomized controlled trials,” BMJ, vol. 330, no. 7490, pp. 516-522, 2005; [44] J. Schmitt, K. Schakel and N. Schmitt, “Systemic treatment of severe atopic eczema: a systematic review,” Acta Derm Venereol, vol. 87, no. 2, p. 100–111, 2007; [45] J. Kim, J. Shin and J. Ko, “Importance of concomitant topical therapy in moderate-to-severe atopic dermatitis treated with cyclosporine,” Dermatol Ther, vol. 29, no. 2, p. 120–125, 2016; [46] M. Schram, E. Roekevisch and M. Leeflang, “A randomized trial of methotrexate versus azathioprine for severe atopic eczema,” J Allergy Clin Immunol, vol. 128, no. 2, pp. 353-359, 2011; [47] E. Guttman-Yassky, N. Dhingra and D. Leung, “New Era of Biological Therapeutics in Atopic Dermatitis,” Expert Opin Biol Ther, vol. 13, no. 4, pp. 549-61, 2013.
